These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10483340)

  • 1. Allele predicted accelerated rate of cognitive decline in Alzheimer's disease.
    Burke D
    West J Med; 1999 Jul; 171(1):23. PubMed ID: 10483340
    [No Abstract]   [Full Text] [Related]  

  • 2. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
    Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
    Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
    Martins CA; Oulhaj A; de Jager CA; Williams JH
    Neurology; 2005 Dec; 65(12):1888-93. PubMed ID: 16380608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.
    Stone DJ; Molony C; Suver C; Schadt EE; Potter WZ
    Pharmacogenomics J; 2010 Jun; 10(3):161-4. PubMed ID: 19997085
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive asymmetries associated with apolipoprotein E genotype in patients with Alzheimer's disease.
    Finton MJ; Lucas JA; Rippeth JD; Bohac DL; Smith GE; Ivnik RJ; Petersen RC; Graff-Radford NR
    J Int Neuropsychol Soc; 2003 Jul; 9(5):751-9. PubMed ID: 12901781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease.
    Camicioli R; Kryscio R
    Neurology; 2005 Dec; 65(12):1855-6. PubMed ID: 16380605
    [No Abstract]   [Full Text] [Related]  

  • 7. Cognitive change and the APOE epsilon 4 allele.
    Deary IJ; Whiteman MC; Pattie A; Starr JM; Hayward C; Wright AF; Carothers A; Whalley LJ
    Nature; 2002 Aug; 418(6901):932. PubMed ID: 12198535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE is associated with age-of-onset, but not cognitive functioning, in late-life depression.
    Butters MA; Sweet RA; Mulsant BH; Ilyas Kamboh M; Pollock BG; Begley AE; Reynolds CF; DeKosky ST
    Int J Geriatr Psychiatry; 2003 Dec; 18(12):1075-81. PubMed ID: 14677138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two studies: long-term cognitive decline after bypass surgery; Alzheimer's gene linked to earlier bypass.
    Compr Ther; 1999 May; 25(5):300-1. PubMed ID: 10390659
    [No Abstract]   [Full Text] [Related]  

  • 10. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.
    Sager MA; Hermann B; La Rue A
    J Geriatr Psychiatry Neurol; 2005 Dec; 18(4):245-9. PubMed ID: 16306248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].
    Rosich-Estragó M; Figuera-Terré L; Mulet-Pérez B; Arrufat-Cardús MT; Pascual San Emeterio A; Arbeola-Rigau I; Labad-Alquézar A; Vilella-Cuadrada E
    Rev Neurol; 2004 May 1-15; 38(9):801-7. PubMed ID: 15152345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E and cognitive performance: a meta-analysis.
    Small BJ; Rosnick CB; Fratiglioni L; Bäckman L
    Psychol Aging; 2004 Dec; 19(4):592-600. PubMed ID: 15584785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics of Alzheimer's disease.
    Burke JR; Roses AD
    Int J Neurol; 1991-1992; 25-26():41-51. PubMed ID: 11980062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.
    Licastro F; Chiappelli M; Grimaldi LM; Morgan K; Kalsheker N; Calabrese E; Ritchie A; Porcellini E; Salani G; Franceschi M; Canal N
    Neurobiol Aging; 2005 Apr; 26(4):449-53. PubMed ID: 15653173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum and Alzheimer's disease.
    Munoz DG
    CMAJ; 1995 Feb; 152(4):468-9. PubMed ID: 7859191
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical utility of apoe allele determination in assessing the need for antioxidant therapy.
    Dreon DM; Peroutkal SJ
    Med Hypotheses; 2001 Mar; 56(3):357-9. PubMed ID: 11359359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of genetic variation of apolipoprotein E in Alzheimer's disease].
    Martínez Lage JM
    Med Clin (Barc); 1999 Oct; 113(12):449-51. PubMed ID: 10570512
    [No Abstract]   [Full Text] [Related]  

  • 18. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic association between the apolipoprotein E (ApoE) gene alleles and various forms of Alzheimer's disease].
    Korovaĭtseva GI; Shcherbatykh TV; Selezneva NV; Gavrilova SI; Golimbet VE; Voskresenskaia NI; Rogaev EI
    Genetika; 2001 Apr; 37(4):529-35. PubMed ID: 11421127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frequency of the APOE-4 allele in Alzheimer's disease and its variation with age in Asturias (Spain)].
    Alvarez V; Alvarez R; Peña J; Lahoz CH; Martínez C; Menéndez-Guisasola L; Salas-Puig J; Morís G; Uría D; Menes BB; Ribacoba R; Vidal JA; Coto E
    Med Clin (Barc); 1999 Oct; 113(12):441-3. PubMed ID: 10570509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.